Key result
Add-on ranolazine lowers fasting plasma glucose by ~5 mg/dL versus standard therapy at 8 weeks.
Why the study?
Does ranolazine added to regular therapy reduce fasting plasma glucose in patients with Type II diabetes mellitus and stable angina?
RCT (n=76)
Open-label
1:1 parallel group by computer-generated randomization chart
No
Does ranolazine added to regular therapy reduce fasting plasma glucose in patients with Type II diabetes mellitus and stable angina?
Answers are grounded in this paper and cite their sources.
Supports ranolazine add-on for glycemic control in T2DM with stable angina; extends its utility beyond anti-anginal effects in RCT evidence.
Objective: The study was aimed to evaluate the effect of Ranolazine on Fasting Plasma Glucose (FPG) in patients of Type II Diabetes Mellitus with Stable Angina as add on therapy. Material and Methods: An open-labeled, randomized, controlled parallel group study was conducted in 76 diagnosed patients of Type II Diabetes Mellitus with Stable Angina at S.N. medical College and Hospital, Agra. The selected patients randomly assigned into 2 groups, Control group (Group 1): was on their regular therapy during the 8-week study period. Test group (Group 2): was on Ranolazine 500mg BD (orally) in addition to their regular therapy during the 8week study period. The FPG measurement was done at baseline, repeated after 4weeks and at the end of treatment (i.e at 8week). All data obtained were expressed as mean
No takes yet. Share an insight, caveat, or question.
Budania et al. (2013) conducted an RCT in Type 2 Diabetes Mellitus with Stable Angina (n=76). Ranolazine vs. Regular therapy alone was evaluated on Fasting Plasma Glucose (FPG, mg/dL) at 8 weeks (p=<0.05). Ranolazine 500 mg twice daily as add-on therapy significantly reduced fasting plasma glucose at 8 weeks compared to regular therapy alone (134.84 vs 139.76 mg/dL, p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: